Aytu BioPharma, Inc.
NCM: AYTULive Quote
📈 ZcoreAI Score
Our AI model analyzes Aytu BioPharma, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get AYTU Z-Score →About Aytu BioPharma, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
📊 Fundamental Analysis
Aytu BioPharma, Inc. demonstrates a profit margin of -39.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -6.5% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -109.2%, which indicates that capital utilization is currently under pressure.
At a current price of $2.55, AYTU currently sits at the 75th percentile of its 52-week range (Range: $0.98 - $3.07).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$27.37M
Trailing P/E
--
Forward P/E
15.00
Beta (5Y)
0.28
52W High
$3.07
52W Low
$0.98
Avg Volume
59K
Day High
Day Low